Literature DB >> 26136909

Small interfering RNA-induced inhibition of epithelial cell transforming sequence 2 suppresses the proliferation, migration and invasion of osteosarcoma cells.

Jie Xie1, Pengfei Lei1, Yihe Hu1.   

Abstract

Osteosarcoma (OS) is the most common malignant tumor in bones. Although the five-year survival rate has improved to ∼60% for patients without metastasis, the prognosis remains poor for patients with metastatic OS. Epithelial cell transforming sequence 2 (ECT2) has been shown to act as an oncogene in human malignancies. More recently, ETC2 was shown to be involved in the development and progression of OS; however, the detailed role of ECT2 in the regulation of cellular biological processes in OS cells remains largely unknown. Therefore, it was investigated in the present study. It was found that the expression of ECT2 was notably increased in OS tissues when compared with that in matched normal adjacent tissues. Furthermore, it was established that the downregulation of ECT2 induced by transfection with ECT2-specific small interfering RNA effectively inhibited OS cell proliferation and induced cell apoptosis. Further investigation revealed that the inhibition of ECT2 expression suppressed OS cell migration and invasion, indicating that the overexpression of ECT2 promotes OS cell migration and invasion, while. In addition, western blotting results indicated that matrix metalloproteinases 2 and 9 may be involved in the ECT2-mediated OS cell invasion. In conclusion, the current study suggested that ECT2 acted as an oncogene in OS, and it may become a promising therapeutic target for the prevention and treatment of OS.

Entities:  

Keywords:  apoptosis; epithelial cell transforming sequence 2; invasion; osteosarcoma; proliferation

Year:  2015        PMID: 26136909      PMCID: PMC4471779          DOI: 10.3892/etm.2015.2306

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  22 in total

Review 1.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

2.  Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients.

Authors:  Masakazu Sano; Nobuyuki Genkai; Naoki Yajima; Naoto Tsuchiya; Junpei Homma; Ryuichi Tanaka; Toru Miki; Ryuya Yamanaka
Journal:  Oncol Rep       Date:  2006-11       Impact factor: 3.906

3.  Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signaling in patients with osteosarcoma.

Authors:  Haoshaqiang Zhang; Zongsheng Yin; Kai Ning; Lei Wang; Rui Guo; Zhe Ji
Journal:  Hum Pathol       Date:  2014-03-05       Impact factor: 3.466

4.  Clinical validation of colorectal cancer biomarkers identified from bioinformatics analysis of public expression data.

Authors:  Yeonjoo Jung; Sanghyuk Lee; Hyung-Seok Choi; Soon-Nam Kim; Eunyoung Lee; Youngah Shin; Jihae Seo; Bumjin Kim; Yeonhwa Jung; Wan Kyu Kim; Ho-Kyung Chun; Woo Yong Lee; Jaesang Kim
Journal:  Clin Cancer Res       Date:  2011-02-08       Impact factor: 12.531

5.  Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells.

Authors:  Shannon P Fortin; Matthew J Ennis; Cassie A Schumacher; Cassandra R Zylstra-Diegel; Bart O Williams; Julianna T D Ross; Jeffrey A Winkles; Joseph C Loftus; Marc H Symons; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2012-05-09       Impact factor: 5.852

Review 6.  The miRNAs in the pathgenesis of osteosarcoma.

Authors:  Wenqing Liang; Bo Gao; Peng Fu; Shuogui Xu; Yu Qian; Qingge Fu
Journal:  Front Biosci (Landmark Ed)       Date:  2013-01-01

7.  Epithelial cell transforming sequence 2 in human oral cancer.

Authors:  Manabu Iyoda; Atsushi Kasamatsu; Takashi Ishigami; Dai Nakashima; Yosuke Endo-Sakamoto; Katsunori Ogawara; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

Review 8.  Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.

Authors:  J PosthumaDeBoer; M A Witlox; G J L Kaspers; B J van Royen
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

9.  Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis.

Authors:  T Tatsumoto; X Xie; R Blumenthal; I Okamoto; T Miki
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

10.  ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.

Authors:  Yoshihiko Murata; Yuko Minami; Reika Iwakawa; Jun Yokota; Shingo Usui; Koji Tsuta; Kouya Shiraishi; Shingo Sakashita; Kaishi Satomi; Tatsuo Iijima; Masayuki Noguchi
Journal:  Cancer Sci       Date:  2014-03-19       Impact factor: 6.716

View more
  5 in total

1.  Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy.

Authors:  Zheng Su; Gaojie Liu; Tingfeng Fang; Yang Wang; Huayao Zhang; Shanglin Yang; Jinxing Wei; Zejian Lv; Langping Tan; Jianping Liu
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  Identification of key biomarkers and functional pathways in osteosarcomas with lung metastasis: Evidence from bioinformatics analysis.

Authors:  Denghua Liu; Rui Zhou; Aiguo Zhou
Journal:  Medicine (Baltimore)       Date:  2021-02-12       Impact factor: 1.817

3.  Network Biomarkers of Bladder Cancer Based on a Genome-Wide Genetic and Epigenetic Network Derived from Next-Generation Sequencing Data.

Authors:  Cheng-Wei Li; Bor-Sen Chen
Journal:  Dis Markers       Date:  2016-02-29       Impact factor: 3.434

4.  Prognostic factors of chondroblastic osteosarcoma and nomogram development for prediction: A population-based, STROBE-compliant study.

Authors:  Cheng Peng; Yingjie Hao; Zhinan Ren; Guangduo Zhu; Lei Yu
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

5.  Upregulation of ECT2 Predicts Adverse Clinical Outcomes and Increases 5-Fluorouracil Resistance in Gastric Cancer Patients.

Authors:  Hua Zhang; Yuan Geng; Chunhui Sun; Jin Yu
Journal:  J Oncol       Date:  2021-07-28       Impact factor: 4.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.